Drug  ||| S:0 E:5 ||| NN
repositioning  ||| S:5 E:19 ||| NN
approaches  ||| S:19 E:30 ||| NNS
for  ||| S:30 E:34 ||| IN
the  ||| S:34 E:38 ||| DT
discovery  ||| S:38 E:48 ||| NN
of  ||| S:48 E:51 ||| IN
new  ||| S:51 E:55 ||| JJ
therapeutics  ||| S:55 E:68 ||| NN
for  ||| S:68 E:72 ||| IN
Alzheimer ||| S:72 E:81 ||| NNP
's  ||| S:81 E:84 ||| POS
disease  ||| S:84 E:92 ||| NN
Alzheimer ||| S:92 E:101 ||| NNP
's  ||| S:101 E:104 ||| POS
disease  ||| S:104 E:112 ||| NN
( ||| S:112 E:113 ||| -LRB-
AD ||| S:113 E:115 ||| NNP
)  ||| S:115 E:117 ||| -RRB-
is  ||| S:117 E:120 ||| VBZ
the  ||| S:120 E:124 ||| DT
most  ||| S:124 E:129 ||| RBS
common  ||| S:129 E:136 ||| JJ
cause  ||| S:136 E:142 ||| NN
of  ||| S:142 E:145 ||| IN
dementia  ||| S:145 E:154 ||| NN
and  ||| S:154 E:158 ||| CC
represents  ||| S:158 E:169 ||| VBZ
one  ||| S:169 E:173 ||| CD
of  ||| S:173 E:176 ||| IN
the  ||| S:176 E:180 ||| DT
highest  ||| S:180 E:188 ||| JJS
unmet  ||| S:188 E:194 ||| JJ
needs  ||| S:194 E:200 ||| NNS
in  ||| S:200 E:203 ||| IN
medicine  ||| S:203 E:212 ||| NN
today ||| S:212 E:217 ||| NN
.  ||| S:217 E:219 ||| .
Drug  ||| S:219 E:224 ||| NN
development  ||| S:224 E:236 ||| NN
efforts  ||| S:236 E:244 ||| NNS
for  ||| S:244 E:248 ||| IN
AD  ||| S:248 E:251 ||| NNP
have  ||| S:251 E:256 ||| VBP
been  ||| S:256 E:261 ||| VBN
encumbered  ||| S:261 E:272 ||| VBN
by  ||| S:272 E:275 ||| IN
largely  ||| S:275 E:283 ||| RB
unsuccessful  ||| S:283 E:296 ||| JJ
clinical  ||| S:296 E:305 ||| JJ
trials  ||| S:305 E:312 ||| NNS
in  ||| S:312 E:315 ||| IN
the  ||| S:315 E:319 ||| DT
last  ||| S:319 E:324 ||| JJ
decade ||| S:324 E:330 ||| NN
.  ||| S:330 E:332 ||| .
Drug  ||| S:332 E:337 ||| NN
repositioning ||| S:337 E:350 ||| NN
,  ||| S:350 E:352 ||| ,
a  ||| S:352 E:354 ||| DT
process  ||| S:354 E:362 ||| NN
of  ||| S:362 E:365 ||| IN
discovering  ||| S:365 E:377 ||| VBG
a  ||| S:377 E:379 ||| DT
new  ||| S:379 E:383 ||| JJ
therapeutic  ||| S:383 E:395 ||| JJ
use  ||| S:395 E:399 ||| NN
for  ||| S:399 E:403 ||| IN
existing  ||| S:403 E:412 ||| VBG
drugs  ||| S:412 E:418 ||| NNS
or  ||| S:418 E:421 ||| CC
drug  ||| S:421 E:426 ||| NN
candidates ||| S:426 E:436 ||| NNS
,  ||| S:436 E:438 ||| ,
is  ||| S:438 E:441 ||| VBZ
an  ||| S:441 E:444 ||| DT
attractive  ||| S:444 E:455 ||| JJ
and  ||| S:455 E:459 ||| CC
timely  ||| S:459 E:466 ||| JJ
drug  ||| S:466 E:471 ||| NN
development  ||| S:471 E:483 ||| NN
strategy  ||| S:483 E:492 ||| NN
especially  ||| S:492 E:503 ||| RB
for  ||| S:503 E:507 ||| IN
AD ||| S:507 E:509 ||| NNP
.  ||| S:509 E:511 ||| .
Compared  ||| S:511 E:520 ||| VBN
with  ||| S:520 E:525 ||| IN
traditional  ||| S:525 E:537 ||| JJ
de  ||| S:537 E:540 ||| FW
novo  ||| S:540 E:545 ||| FW
drug  ||| S:545 E:550 ||| NN
development ||| S:550 E:561 ||| NN
,  ||| S:561 E:563 ||| ,
time  ||| S:563 E:568 ||| NN
and  ||| S:568 E:572 ||| CC
cost  ||| S:572 E:577 ||| NN
are  ||| S:577 E:581 ||| VBP
reduced  ||| S:581 E:589 ||| VBN
as  ||| S:589 E:592 ||| IN
the  ||| S:592 E:596 ||| DT
safety  ||| S:596 E:603 ||| NN
and  ||| S:603 E:607 ||| CC
pharmacokinetic  ||| S:607 E:623 ||| JJ
properties  ||| S:623 E:634 ||| NNS
of  ||| S:634 E:637 ||| IN
most  ||| S:637 E:642 ||| RBS
repositioning  ||| S:642 E:656 ||| JJ
candidates  ||| S:656 E:667 ||| NNS
have  ||| S:667 E:672 ||| VBP
already  ||| S:672 E:680 ||| RB
been  ||| S:680 E:685 ||| VBN
determined ||| S:685 E:695 ||| VBN
.  ||| S:695 E:697 ||| .
A  ||| S:697 E:699 ||| DT
majority  ||| S:699 E:708 ||| NN
of  ||| S:708 E:711 ||| IN
drug  ||| S:711 E:716 ||| NN
repositioning  ||| S:716 E:730 ||| NN
efforts  ||| S:730 E:738 ||| NNS
for  ||| S:738 E:742 ||| IN
AD  ||| S:742 E:745 ||| NNP
have  ||| S:745 E:750 ||| VBP
been  ||| S:750 E:755 ||| VBN
based  ||| S:755 E:761 ||| VBN
on  ||| S:761 E:764 ||| IN
positive  ||| S:764 E:773 ||| JJ
clinical  ||| S:773 E:782 ||| JJ
or  ||| S:782 E:785 ||| CC
epidemiological  ||| S:785 E:801 ||| JJ
observations  ||| S:801 E:814 ||| NNS
or  ||| S:814 E:817 ||| CC
in  ||| S:817 E:820 ||| IN
vivo  ||| S:820 E:825 ||| JJ
efficacy  ||| S:825 E:834 ||| NN
found  ||| S:834 E:840 ||| VBD
in  ||| S:840 E:843 ||| IN
mouse  ||| S:843 E:849 ||| NN
models  ||| S:849 E:856 ||| NNS
of  ||| S:856 E:859 ||| IN
AD ||| S:859 E:861 ||| NNP
.  ||| S:861 E:863 ||| .
More  ||| S:863 E:868 ||| RBR
systematic ||| S:868 E:878 ||| JJ
,  ||| S:878 E:880 ||| ,
multidisciplinary  ||| S:880 E:898 ||| JJ
approaches  ||| S:898 E:909 ||| NNS
will  ||| S:909 E:914 ||| MD
further  ||| S:914 E:922 ||| RB
facilitate  ||| S:922 E:933 ||| VB
drug  ||| S:933 E:938 ||| NN
repositioning  ||| S:938 E:952 ||| NN
for  ||| S:952 E:956 ||| IN
AD ||| S:956 E:958 ||| NNP
.  ||| S:958 E:960 ||| .
Some  ||| S:960 E:965 ||| DT
experimental  ||| S:965 E:978 ||| JJ
approaches  ||| S:978 E:989 ||| NNS
include  ||| S:989 E:997 ||| VBP
unbiased  ||| S:997 E:1006 ||| JJ
phenotypic  ||| S:1006 E:1017 ||| NNS
screening  ||| S:1017 E:1027 ||| VBP
using  ||| S:1027 E:1033 ||| VBG
the  ||| S:1033 E:1037 ||| DT
library  ||| S:1037 E:1045 ||| NN
of  ||| S:1045 E:1048 ||| IN
available  ||| S:1048 E:1058 ||| JJ
drug  ||| S:1058 E:1063 ||| NN
collections  ||| S:1063 E:1075 ||| NNS
in  ||| S:1075 E:1078 ||| IN
physiologically  ||| S:1078 E:1094 ||| JJ
relevant  ||| S:1094 E:1103 ||| JJ
model  ||| S:1103 E:1109 ||| NN
systems  ||| S:1109 E:1117 ||| NNS
( ||| S:1117 E:1118 ||| -LRB-
e.g.  ||| S:1118 E:1123 ||| NNP
stem  ||| S:1123 E:1128 ||| VBP
cell-derived  ||| S:1128 E:1141 ||| JJ
neurons  ||| S:1141 E:1149 ||| NN
or  ||| S:1149 E:1152 ||| CC
glial  ||| S:1152 E:1158 ||| JJ
cells ||| S:1158 E:1163 ||| NNS
) ||| S:1163 E:1164 ||| -RRB-
,  ||| S:1164 E:1166 ||| ,
computational  ||| S:1166 E:1180 ||| JJ
prediction  ||| S:1180 E:1191 ||| NN
and  ||| S:1191 E:1195 ||| CC
selection  ||| S:1195 E:1205 ||| NN
approaches  ||| S:1205 E:1216 ||| NNS
that  ||| S:1216 E:1221 ||| IN
leverage  ||| S:1221 E:1230 ||| NN
the  ||| S:1230 E:1234 ||| DT
accumulating  ||| S:1234 E:1247 ||| JJ
data  ||| S:1247 E:1252 ||| NNS
resulting  ||| S:1252 E:1262 ||| VBG
from  ||| S:1262 E:1267 ||| IN
RNA  ||| S:1267 E:1271 ||| NNP
expression  ||| S:1271 E:1282 ||| NN
profiles ||| S:1282 E:1290 ||| NNS
,  ||| S:1290 E:1292 ||| ,
and  ||| S:1292 E:1296 ||| CC
genome-wide  ||| S:1296 E:1308 ||| JJ
association  ||| S:1308 E:1320 ||| NN
studies ||| S:1320 E:1327 ||| NNS
.  ||| S:1327 E:1329 ||| .
This  ||| S:1329 E:1334 ||| DT
review  ||| S:1334 E:1341 ||| NN
will  ||| S:1341 E:1346 ||| MD
summarize  ||| S:1346 E:1356 ||| VB
several  ||| S:1356 E:1364 ||| JJ
notable  ||| S:1364 E:1372 ||| JJ
strategies  ||| S:1372 E:1383 ||| NNS
and  ||| S:1383 E:1387 ||| CC
representative  ||| S:1387 E:1402 ||| JJ
examples  ||| S:1402 E:1411 ||| NNS
of  ||| S:1411 E:1414 ||| IN
drug  ||| S:1414 E:1419 ||| NN
repositioning  ||| S:1419 E:1433 ||| NN
for  ||| S:1433 E:1437 ||| IN
AD ||| S:1437 E:1439 ||| NNP
.  ||| S:1439 E:1441 ||| .
